6 terminated, 3 recruiting, 2 active not recruiting, 2 completed. 9 Phase 2, 4 Phase 1, 2 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Terminated 5, Completed 2, Active not recruiting 1, Recruiting 1 |
| Phase 1 | 4 | Recruiting 2, Terminated 2 |
| Early Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
Follow ITB-Med LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tolerance Through Mixed Chimerism (Sip-Tego) Combined Kidney/Bone Marrow Transplant, Donation of Kidney / Bone Marrow, Conditioning Regimen (Rituxan, Siplizumab (or ATGAM), Cyclophosphamide, Tegoprubart) - Kidney Failure, Transplant Recipient (Kidney) | Early Phase 1 | Active not recruiting | Tatsuo Kawai, MD, PhD | 12 | 2025-05-31 | 2026-09-25 |
| Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa. Siplizumab - Hidradenitis Suppurativa | Early Phase 1 | Recruiting | University of Alabama at Birmingham | 12 | 2025-05-09 | 2026-09-01 |
| A Study of SIPLIZUMAB in AILD and LT Patients Siplizumab - Autoimmune Liver Disease, Liver Transplant Disorder | Phase 1 | Recruiting | Elizabeth C. Verna | 8 | 2024-09-11 | 2025-11-24 |
| A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients TCD601 - ALS | Phase 1 | Terminated | ITB-Med LLC | 7 | 2024-04-16 | 2026-07-17 |
| A Study of TCD601 in de Novo Renal Transplant Recipients TCD601, belatacept, ATG - Renal Transplantation | Phase 2 | Completed | ITB-Med LLC | 76 | 2023-12-28 | 2026-05-05 |
| Delayed Tolerance Through Mixed Chimerism Bone Marrow Transplant, Peripheral Blood Stem Cell Collection, Fludarabine - Kidney Failure, Kidney Transplant; Complications | Phase 1 / Phase 2 | Recruiting | Massachusetts General Hospital | 20 | 2023-10-01 | 2026-09-28 |
| Siplizumab for Sickle Cell Disease Transplant Siplizumab, Exchange Transfusion, Total Body Irradiation - Anemia, Sickle Cell | Phase 1 / Phase 2 | Terminated | Columbia University | 1 | 2023-09-28 | 2026-06-10 |
| A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients TCD601, Placebo - Diabetes Mellitus, Type 1 | Phase 2 | Terminated | ITB-Med LLC | 9 | 2023-01-23 | 2025-08-14 |
| A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA) TCD601 - Kidney Transplantation | Phase 2 | Terminated | ITB-Med LLC | 4 | 2023-01-17 | 2026-02-06 |
| A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE) TCD601 - Kidney Transplantation | Phase 2 | Terminated | ITB-Med LLC | 7 | 2022-12-14 | 2026-07-13 |
| A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation TCD601, Cyclophosphamide, TAC - Liver Transplantation | Phase 2 | Active not recruiting | ITB-Med LLC | 12 | 2022-06-29 | 2024-11-27 |
| A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation TCD601, Tacrolimus (TAC), Corticosteroids (CS) - Kidney Transplantation | Phase 2 | Terminated | ITB-Med LLC | 33 | 2021-06-06 | 2026-03-12 |
| A Dose Escalation Study in de Novo Renal Transplantation TCD601, Tacrolimus (TAC), Corticosteroids (CS) - Kidney Transplantation | Phase 2 | Completed | ITB-Med LLC | 13 | 2021-05-26 | 2025-02-27 |
Renal Insufficiency (2) · Amyotrophic Lateral Sclerosis (1) · Anemia, Sickle Cell (1) · Cholangitis, Sclerosing (1) · Diabetes Mellitus, Type 1 (1) · Disease (1) · End Stage Liver Disease (1) · Hepatitis, Autoimmune (1) · Hidradenitis Suppurativa (1) · Liver Cirrhosis (1) · Sickle Cell Trait (1)
siplizumab (9) · Adrenal Cortex Hormones (4) · Cyclophosphamide (4) · Mycophenolic Acid (4) · Tacrolimus (4) · Rituximab (3) · Antilymphocyte Serum (2) · Abatacept (1) · Biosimilar Pharmaceuticals (1) · Bone Marrow Transplantation (1) · Exchange Transfusion, Whole Blood (1) · Mesna (1) · Sirolimus (1) · Transplantation Conditioning (1) · Whole-Body Irradiation (1)
United States (9) · Sweden (4) · Spain (2) · Austria (1) · Belgium (1) · Italy (1) · South Korea (1) · United Kingdom (1)
Fredrik Juhlin (3) · Tracy Killingsworth (2) · Elizabeth Verna, MD (1) · Fredrik Julin (1) · Kellie Kennon, BSN (1) · Markus Y Mapara, MD, PhD (1) · Nick Hryciw, MA (1) · Sarah McClees, MD (1) · Tatsuo Kawai (1) · Tatsuo Kawai, MD PhD (1)